ArticleTheranostics2020
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 36 citations in OpenAlex.
- Trial
- Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study.JMIR research protocols · 2026Article
- Liquid Biopsies and Molecular Imaging for Precise Cancer Management.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617.The oncologist · 2025Article
- Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3).European journal of nuclear medicine and molecular imaging · 2025Article
- [PSMA radioligand therapy-State of the art].Urologie (Heidelberg, Germany) · 2025Review
- Synergizing Liquid Biopsy and Hybrid PET Imaging for Prognostic Assessment in Prostate Cancer: A Focus Review.Biomolecules · 2025Review
- PROTAC technology for prostate cancer treatment.Acta materia medica · 2025Article
- Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancer management and research · 2025Review
- Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer.Frontiers in oncology · 2025Review
- Advanced single-cell and spatial analysis with high-multiplex characterization of circulating tumor cells and tumor tissue in prostate cancer: Unveiling resistance mechanisms with the CoDuCo in situ assay.Biomarker research · 2024Article
- Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide Therapy in Oncology.Pharmaceutics · 2024Review
- ENO2, a Glycolytic Enzyme, Contributes to Prostate Cancer Metastasis: A Systematic Review of Literature.Cancers · 2024Review
- Review
- Nomogram-based prognostic model construction for progression to castration-resistant prostate cancer in patients with high tumor burden and osseous metastatic prostate cancer.American journal of cancer research · 2024Article
- BeyondMolecular therapy oncolytics · 2023Review
- Review
- Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials.Therapeutic advances in medical oncology · 2023Review
- Single Center Experience with a 4-WeekCancers · 2022Article
- Insights into Circulating Tumor Cell Clusters: A Barometer for Treatment Effects and Prognosis for Prostate Cancer Patients.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.